Financial Partners Group LLC Invests $6.35 Million in Humana Inc. (NYSE:HUM)

Financial Partners Group LLC purchased a new position in Humana Inc. (NYSE:HUM) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,320 shares of the insurance provider’s stock, valued at approximately $6,352,000. Humana makes up 2.5% of Financial Partners Group LLC’s investment portfolio, making the stock its 16th biggest holding.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Rakuten Securities Inc. acquired a new stake in shares of Humana in the fourth quarter valued at $25,000. Gradient Investments LLC lifted its holdings in shares of Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after buying an additional 40 shares during the period. Cetera Trust Company N.A acquired a new stake in shares of Humana in the fourth quarter valued at $28,000. Private Wealth Management Group LLC acquired a new stake in shares of Humana in the fourth quarter valued at $32,000. Finally, Carolinas Wealth Consulting LLC lifted its holdings in shares of Humana by 274.1% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after buying an additional 74 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Up 3.2 %

HUM stock traded up $11.53 during mid-day trading on Friday, hitting $373.65. The stock had a trading volume of 5,489,806 shares, compared to its average volume of 1,076,536. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $530.54. The company has a fifty day moving average of $343.78 and a 200 day moving average of $351.23. The stock has a market capitalization of $45.02 billion, a price-to-earnings ratio of 23.27, a PEG ratio of 2.16 and a beta of 0.53.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the firm posted $9.38 EPS. The business’s revenue was up 10.7% compared to the same quarter last year. On average, equities analysts expect that Humana Inc. will post 16.27 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 0.95%. The ex-dividend date is Friday, June 28th. Humana’s payout ratio is currently 22.04%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HUM shares. Oppenheimer cut their price objective on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. TD Cowen cut their price objective on Humana from $427.00 to $396.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Bank of America upped their target price on Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a report on Monday, May 20th. Morgan Stanley started coverage on Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $360.00 target price on shares of Humana in a report on Wednesday, June 12th. Fourteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $409.55.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.